|
|
 Previous Article | Table of Contents | Next Article 
Recombinant human megakaryocyte growth and development factor stimulates
thrombocytopoiesis in normal nonhuman primates
AM Farese, P Hunt, T Boone and TJ MacVittie
Armed Forces Radiobiology Research Institute, Bethesda, MD 20889-5603, USA.
Megakaryocyte growth and development factor (MGDF) is a novel cytokine that
binds to the c-mpl receptor and stimulates megakaryocyte development in
vitro and in vivo. This report describes the ability of recombinant human
(r-Hu) MGDF to affect megakaryocytopoiesis in normal nonhuman primates.
r-HuMGDF was administered subcutaneously to normal, male rhesus monkeys
once per day for 10 consecutive days at dosages of 2.5, 25, or 250
micrograms/kg of body weight. Bone marrow and peripheral blood were assayed
for clonogenic activity and peripheral blood counts were monitored.
Circulating platelet counts increased significantly (P < .05) for all
doses within 6 days of r-HuMGDF administration and reached maximal levels
between day 12 and day 14 postcytokine administration. The 2.5, 25.0, and
250.0 micrograms/kg/d doses elicited peak mean platelet counts that were
592%, 670%, and 449% of baseline, respectively. Bone marrow-derived
clonogenic data showed significant increases in the concentration of
megakaryocyte (MEG)- colony-forming unit (CFU) and
granulocyte-erythroid-macrophage- megakaryocyte (GEMM)-CFU, whereas that of
granulocyte-macrophage (GM)- CFU and burst-forming unit-erythroid (BFU-e)
remained unchanged during the administration of r-HuMGDF. These data show
that r-HuMGDF is a potent stimulator of thrombocytopoiesis in the normal
nonhuman primate.
Volume 86,
Issue 1,
pp. 54-59,
07/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
Ann. Onc.,
November 1, 2007;
18(11):
1842 - 1850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Feese, T. Tamada, Y. Kato, Y. Maeda, M. Hirose, Y. Matsukura, H. Shigematsu, T. Muto, A. Matsumoto, H. Watarai, et al.
Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment
PNAS,
February 17, 2004;
101(7):
1816 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Nagata, J. Yoshikawa, A. Hashimoto, M. Yamamoto, A. H. Payne, and K. Todokoro
Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol
Genes & Dev.,
December 1, 2003;
17(23):
2864 - 2869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Hitchcock, T. M. Skerry, M. R. Howard, and P. G. Genever
NMDA receptor-mediated regulation of human megakaryocytopoiesis
Blood,
August 15, 2003;
102(4):
1254 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Challier, L. Cocault, R. Berthier, N. Binart, I. Dusanter-Fourt, G. Uzan, and M. Souyri
The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells
Blood,
August 28, 2002;
100(6):
2063 - 2070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ando, Y. Iwamoto, A. Suda, K. Tsuchiya, and H. Nihei
New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels
Blood,
February 15, 2001;
97(4):
915 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer, K. Miller, R. A. Larson, P. C. Amrein, J. H. Antin, V. J. Zani, and R. M. Stone
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
Blood,
April 15, 2000;
95(8):
2530 - 2535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gainsford, H. Nandurkar, D. Metcalf, L. Robb, C. G. Begley, and W. S. Alexander
The residual megakaryocyte and platelet production in c-Mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
Blood,
January 15, 2000;
95(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Archimbaud, O. G. Ottmann, J. A. L. Yin, K. Lechner, H. Dombret, M. A. Sanz, G. Heil, P. Fenaux, W. Brugger, A. Barge, et al.
A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia
Blood,
December 1, 1999;
94(11):
3694 - 3701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sakamaki, Y. Hirayama, T. Matsunaga, H. Kuroda, T. Kusakabe, T. Akiyama, Y. Konuma, K. Sasaki, N. Tsuji, T. Okamoto, et al.
Transforming Growth Factor-beta 1 (TGF-beta 1) Induces Thrombopoietin From Bone Marrow Stromal Cells, Which Stimulates the Expression of TGF-beta Receptor on Megakaryocytes and, in Turn, Renders Them Susceptible to Suppression by TGF-beta Itself With High Specificity
Blood,
September 15, 1999;
94(6):
1961 - 1970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Altun, M. Arici, I. C. Haznedaroglu, C. Usalan, Y. Erdem, U. Yasavul, C. Turgan, S. Caglar, and S. Kirazli
Serum thrombopoietin levels in haemodialysis patients: involvement of arteriovenous fistula
Nephrol. Dial. Transplant.,
September 1, 1999;
14(9):
2173 - 2177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Neelis, T. P. Visser, W. Dimjati, G. R. Thomas, P. J. Fielder, D. Bloedow, D. L. Eaton, and G. Wagemaker
A Single Dose of Thrombopoietin Shortly After Myelosuppressive Total Body Irradiation Prevents Pancytopenia in Mice by Promoting Short-Term Multilineage Spleen-Repopulating Cells at the Transient Expense of Bone Marrow-Repopulating Cells
Blood,
September 1, 1998;
92(5):
1586 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Solar, W. G. Kerr, F. C. Zeigler, D. Hess, C. Donahue, F. J. de Sauvage, and D. L. Eaton
Role of c-mpl in Early Hematopoiesis
Blood,
July 1, 1998;
92(1):
4 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gainsford, A. W. Roberts, S. Kimura, D. Metcalf, G. Dranoff, R. C. Mulligan, C. G. Begley, L. Robb, and W. S. Alexander
Cytokine Production and Function in c-mpl-Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production
Blood,
April 15, 1998;
91(8):
2745 - 2752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kimura, A. W. Roberts, D. Metcalf, and W. S. Alexander
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin
PNAS,
February 3, 1998;
95(3):
1195 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Daw, J. T. Arnold, B. A. Abushullaih, P. E. Stenberg, M. M. White, D. Jayawardene, D. Kumar Srivastava, and C. W. Jackson
A Single Intravenous Dose of Murine Megakaryocyte Growth and Development Factor Potently Stimulates Platelet Production, Challenging the Necessity for Daily Administration
Blood,
January 15, 1998;
91(2):
466 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shibuya, H. Akahori, K. Takahashi, E. Tahara, T. Kato, and H. Miyazaki
Multilineage Hematopoietic Recovery by a Single Injection of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Myelosuppressed Mice
Blood,
January 1, 1998;
91(1):
37 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Villeval, K. Cohen-Solal, M. Tulliez, S. Giraudier, J. Guichard, S. A. Burstein, E. M. Cramer, W. Vainchenker, and F. Wendling
High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice
Blood,
December 1, 1997;
90(11):
4369 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Dale, J. L. Nichol, D. A. Rich, D. M. Best, S. J. Slichter, W. Sheridan, and P. Hunt
Chronic Thrombocytopenia Is Induced in Dogs by Development of Cross-Reacting Antibodies to the MpL Ligand
Blood,
November 1, 1997;
90(9):
3456 - 3461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abraham and R. L. Basser
Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies
Oncologist,
October 1, 1997;
2(5):
311 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Neelis, L. Qingliang, G. R. Thomas, B. L. Cohen, D. L. Eaton, and G. Wagemaker
Prevention of Thrombocytopenia by Thrombopoietin in Myelosuppressed Rhesus Monkeys Accompanied by Prominent Erythropoietic Stimulation and Iron Depletion
Blood,
July 1, 1997;
90(1):
58 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Goncalves, C. Lacout, J.-L. Villeval, F. Wendling, W. Vainchenker, and D. Dumenil
Thrombopoietin Does Not Induce Lineage-Restricted Commitment of Mpl-R Expressing Pluripotent Progenitors But Permits Their Complete Erythroid and Megakaryocytic Differentiation
Blood,
May 15, 1997;
89(10):
3544 - 3553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Basser, J. E.J. Rasko, K. Clarke, J. Cebon, M. D. Green, A. P. Grigg, J. Zalcberg, B. Cohen, J. O'Byrne, D. M. Menchaca, et al.
Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer
Blood,
May 1, 1997;
89(9):
3118 - 3128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Broudy, N. L. Lin, D. F. Sabath, T. Papayannopoulou, and K. Kaushansky
Human Platelets Display High-Affinity Receptors for Thrombopoietin
Blood,
March 15, 1997;
89(6):
1896 - 1904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhou, C. F. Toombs, T. Zou, J. Guo, and M. O. Robinson
Transgenic Mice Overexpressing Human c-mpl Ligand Exhibit Chronic Thrombocytosis and Display Enhanced Recovery From 5-Fluorouracil or Antiplatelet Serum Treatment
Blood,
March 1, 1997;
89(5):
1551 - 1559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fanucchi, J. Glaspy, J. Crawford, J. Garst, R. Figlin, W. Sheridan, D. Menchaca, D. Tomita, H. Ozer, and L. Harker
Effects of Polyethylene Glycol-Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung Cancer
N. Engl. J. Med.,
February 6, 1997;
336(6):
404 - 409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Levin
Thrombopoietin -- Clinically Realized?
N. Engl. J. Med.,
February 6, 1997;
336(6):
434 - 436.
[Full Text]
|
|
|
|
|
|
|
J. T. Arnold, N. C. Daw, P. E. Stenberg, D. Jayawardene, D. K. Srivastava, and C. W. Jackson
A Single Injection of Pegylated Murine Megakaryocyte Growth and Development Factor (MGDF ) Into Mice Is Sufficient to Produce a Profound Stimulation of Megakaryocyte Frequency, Size, and Ploidization
Blood,
February 1, 1997;
89(3):
823 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kuter
Thrombopoietin: Biology and Clinical Applications
Oncologist,
February 1, 1996;
1(1):
98 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
